Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Advanced Gastric and Gastroesophageal Junction Cancer: Evidence, Sequencing, Patient Selection, and Clinical Decision-Making.
T-DXd offers a targeted treatment option for HER2-positive advanced gastric cancers, with clinical evidence guiding patient selection and toxicity management strategies.
To provide a clinically oriented review of trastuzumab deruxtecan (T-DXd) in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma, focusing on evidence, post-progression HER2 reassessment, second-line sequencing, patient selection, regional implementation, and toxicity management. The record is retained for conservative triage based on its relevance and randomized controlled trial.
What the study was
- Study design
- Randomized controlled trial
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- J Gastrointest Cancer
Why it surfaced
Retained as a randomized controlled trial relevant to Early cancer detection; scoring is conservative from PubMed metadata and abstract only.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.